Sugi Predict

Sugi Predict / Compounds / D-Histidine

D-Histidine

D-Histidine

SCHEMBL288043

N[C@H](Cc1cnc[nH]1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 1.00
▸ SLC7A5 Q01650 1/20 1.00
▸ CPB2 Q96IY4 1/20 0.59
▸ ALDH1A1 P00352 4/20 0.58
▸ HRH4 Q9H3N8 3/20 0.58
▸ HRH3 Q9Y5N1 3/20 0.58
▸ NFKB1 P19838 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ GLA P06280 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ THPO P40225 1/20 0.58
▸ LMNA P02545 1/20 0.56
▸ APEX1 P27695 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ GABRA1 P14867 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ GABRR1 P24046 1/20 0.55
▸ GABRR2 P28476 1/20 0.55
▸ GABRA5 P31644 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL28071764 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL30852263 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL3260 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL137600 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL388560 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL19974306 1.00 CYP3A4 (1.00) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25357958 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25267810 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL6005501 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4
Histidine SCHEMBL25362582 0.98 CYP3A4 (0.97) CYP3A4SLC7A5CPB2ALDH1A1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101790538-B Ucagon/glp-1 receptor co-agonists INDIANA UNVERSITY RES AND TECH 2014-07-30 — — CN claimed
CN-101578102-B Glucagon analogs exhibiting enhanced solubility in physiological pH buffers UNIV INDIANA RES & TECH CORP 2013-07-17 — — CN claimed
CN-101790538-A Hyperglycemic-glycogenolytic factor/GLP-1 receptor co-agonists INDIANA UNVERSITY RES AND TECH 2010-07-28 — — CN claimed
US-20230002790-A1 POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2023-01-05 — — US disclosed
EP-2771696-B1 METHODS MAKING USE OF PANELS OF METABOLITES FOR THE DIAGNOSIS AND DIFFERENTIATION OF NEONATAL ENCEPHALOPATHY INFANDX AG (DE) 2022-09-14 — — EP disclosed
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS THE JOHNS HOPKINS UNIVERSITY 2022-05-19 — — US disclosed
US-11313866-B2 Method of diagnosing and treating asphyxia INFANDX AG (DE) 2022-04-26 — — US disclosed
EP-3829624-A1 COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHIPHILIC COMPOUND CONTAINING HYDROPHOBIC RADICALS Adocia (FR) 2021-06-09 — — EP disclosed
EP-2249161-B1 Method of diagnosing asphyxia INFANDX AG (DE) 2020-05-13 — — EP disclosed
WO-2020025824-A1 INJECTABLE SOLUTION AT PH 7, COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5, AT LEAST ONE IONIC SPECIES, AND AN AMPHIPHILIC COMPOUND BEARING HYDROPHOBIC RADICALS ADOCIA (FR) 2020-02-06 — — WO disclosed
WO-2020025825-A1 INJECTABLE SOLUTION HAVING PH 7 AND COMPRISING HUMAN GLUCAGON, AT LEAST ONE IONIC SPECIES, AND AN AMPHIPHILIC COMPOUND BEARING HYDROPHOBIC RADICALS ADOCIA (FR) 2020-02-06 — — WO disclosed
EP-1250154-A2 G-CSF CONJUGATES Maxygen Holdings Ltd (US) 2002-10-23 — — EP disclosed
WO-2002081520-A2 SINGLE CHAIN DIMERIC POLYPEPTIDES DERIVED FROM THE VEGF FAMILY MAXYGEN HOLDINGS LTD. (KY) 2002-10-17 — — WO disclosed
WO-2002081507-A2 INTERFERON GAMMA POLYPEPTIDE VARIANTS MAXYGEN HOLDINGS LTD. (KY) 2002-10-17 — — WO disclosed
WO-2002064782-A2 RANK LIGAND-BINDING POLYPEPTIDES MAXYGEN HOLDINGS LTD. (KY) 2002-08-22 — — WO disclosed
WO-2002032461-A2 PROTEIN C OR ACTIVATED PROTEIN C-LIKE MOLECULES MAXYGEN APS (DK) 2002-04-25 — — WO disclosed
WO-2001068141-A2 DISPERSIONS OF POLYPEPTIDE CONJUGATES MAXYGEN APS (DK) 2001-09-20 — — WO disclosed
WO-2001058493-A1 CONJUGATES OF FOLLICLE STIMULATING HORMONES MAXYGEN APS (DK) 2001-08-16 — — WO disclosed
WO-2001058935-A2 FACTOR VII OR VIIa-LIKE MOLECULES MAXYGEN APS (DK) 2001-08-16 — — WO disclosed
WO-2001051510-A2 G-CSF CONJUGATES MAXYGEN HOLDINGS LTD (US) 2001-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS PBK, MICA, STAT3 CYP3A4 4838/4885SLC7A5 3680/4885CPB2 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.